SymBio Pharmaceuticals Limited
SYMQY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $47 | $6,126 | $9,287 | $8,725 |
| - Cash | $23 | $3,054 | $3,615 | $3,963 |
| + Debt | $16 | $1,300 | $700 | $0 |
| Enterprise Value | $40 | $4,373 | $6,373 | $4,762 |
| Revenue | $2 | $383 | $264 | $554 |
| % Growth | -99.4% | 44.9% | -52.3% | – |
| Gross Profit | $1 | $291 | $202 | $429 |
| % Margin | 62.3% | 76.1% | 76.7% | 77.4% |
| EBITDA | -$8 | -$7 | -$135 | -$1,061 |
| % Margin | -361.3% | -1.8% | -51.1% | -191.7% |
| Net Income | -$8 | -$1,048 | -$1,321 | -$988 |
| % Margin | -369.1% | -273.8% | -500.5% | -178.5% |
| EPS Diluted | -0.16 | -22.16 | -27.95 | -21.55 |
| % Growth | 99.3% | 20.7% | -29.7% | – |
| Operating Cash Flow | – | $0 | $0 | $0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | $0 | $0 | $0 |